Investigational New Drugs

, Volume 30, Issue 2, pp 794–802

A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate

  • Justine Yang Bruce
  • Jens Eickhoff
  • Roberto Pili
  • Theodore Logan
  • Michael Carducci
  • Jamie Arnott
  • Anthony Treston
  • George Wilding
  • Glenn Liu
PHASE II STUDIES

Summary

Background Current treatment for metastatic renal cell cancer with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKI) have provided improved overall survival, but complete responses are rare. We conducted a multicenter phase II study to evaluate the objective response rate of 2-methoxyestradiol (2ME2 NCD) alone and in combination with sunitinib for patients with metastatic renal cell carcinoma who have progressed on sunitinib alone. Methods Adults with metastatic kidney cancer were stratified depending on whether they were still taking sunitinib or had discontinued sunitinib therapy at the time of registration. Patients were treated with 2ME2 NCD alone or in combination with sunitinib. The primary endpoint was objective response rate. Results In total, 17 patients were enrolled, and 12 were evaluable for response (arm A, n = 7; arm b, n = 5). In arm A, four patients had the best response of stable disease, and three patients developed disease progression. In arm B, three patients had a best response of stable disease, and two patients had disease progression. One patient continued to receive treatment for a total of 14 cycles before developing disease progression. Fatigue was the most common observed toxicities. Thirty five percent of patients required discontinuation of therapy secondary to toxicities. Conclusions 2ME2 NCD had minimal anti-tumor activity, with no observed objective responses. The study was terminated because 2ME2 NCD was not found to be tolerable at the recommended phase 2 dose in this patient population. A newer 2ME2 analog is in development with a more favorable toxicity profile and increased potency.

Keywords

Renal cell carcinoma Clinical trials Phase II 2-methoxyestradiol Sunitinib malate Antiangiogenic agent 

References

  1. 1.
    American Cancer Society (2010) Cancer facts and figures 2010. American Cancer Society, AtlantaGoogle Scholar
  2. 2.
    Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators (1999). Lancet 353(9146):14–17. doi:S0140673698035442
  3. 3.
    Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, Juusela H, Rintala E, Hietanen P, Kellokumpu-Lehtinen PL (1999) Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17(9):2859–2867PubMedGoogle Scholar
  4. 4.
    Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124. doi:356/2/115 PubMedCrossRefGoogle Scholar
  5. 5.
    Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134. doi:356/2/125 PubMedCrossRefGoogle Scholar
  6. 6.
    Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26(33):5422–5428. doi:JCO.2008.16.9847 PubMedCrossRefGoogle Scholar
  7. 7.
    Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol doi:JCO.2009.23.9764
  8. 8.
    Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P (2003) 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3(4):363–375. doi:S1535610803000771 PubMedCrossRefGoogle Scholar
  9. 9.
    Attalla H, Makela TP, Adlercreutz H, Andersson LC (1996) 2-Methoxyestradiol arrests cells in mitosis without depolymerizing tubulin. Biochem Biophys Res Commun 228(2):467–473. doi:S0006-291X(96)91683-6 PubMedCrossRefGoogle Scholar
  10. 10.
    Yue TL, Wang X, Louden CS, Gupta S, Pillarisetti K, Gu JL, Hart TK, Lysko PG, Feuerstein GZ (1997) 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol Pharmacol 51(6):951–962PubMedGoogle Scholar
  11. 11.
    LaVallee TM, Zhan XH, Johnson MS, Herbstritt CJ, Swartz G, Williams MS, Hembrough WA, Green SJ, Pribluda VS (2003) 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res 63(2):468–475PubMedGoogle Scholar
  12. 12.
    Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L (1994) The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368(6468):237–239. doi:10.1038/368237a0 PubMedCrossRefGoogle Scholar
  13. 13.
    Mooberry SL (2003) Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist Updat 6(6):355–361. doi:S1368764603001043 PubMedCrossRefGoogle Scholar
  14. 14.
    Lakhani NJ, Sarkar MA, Venitz J, Figg WD (2003) 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 23(2):165–172PubMedCrossRefGoogle Scholar
  15. 15.
    Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D, Parr A, Nguyen D, Yang SX, Steinberg SM, Venitz J, Sparreboom A, Figg WD (2006) Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther 5(1):22–27. doi:2349 PubMedCrossRefGoogle Scholar
  16. 16.
    Takeuchi H, Yamamoto H, Kawashima Y (2001) Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev 47(1):39–54. doi:S0169409X00001204 PubMedCrossRefGoogle Scholar
  17. 17.
    Tevaarwerk AJ, Holen KD, Alberti DB, Sidor C, Arnott J, Quon C, Wilding G, Liu G (2009) Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies. Clin Cancer Res 15(4):1460–1465. doi:15/4/1460 PubMedCrossRefGoogle Scholar
  18. 18.
    Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P (1999) Measurement of clinical and subclinical tumour response using [18 F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35(13):1773–1782. doi:S0959804999002294 PubMedCrossRefGoogle Scholar
  19. 19.
    Matei D, Schilder J, Sutton G, Perkins S, Breen T, Quon C, Sidor C (2009) Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Gynecol Oncol 115(1):90–96. doi:S0090-8258(09)00381-3 PubMedCrossRefGoogle Scholar
  20. 20.
    Sweeney C, Liu G, Yiannoutsos C, Kolesar J, Horvath D, Staab MJ, Fife K, Armstrong V, Treston A, Sidor C, Wilding G (2005) A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res 11(18):6625–6633. doi:11/18/6625 PubMedCrossRefGoogle Scholar
  21. 21.
    Eichelberg C, Heuer R, Chun FK, Hinrichs K, Zacharias M, Huland H, Heinzer H (2008) Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 54(6):1373–1378. doi:S0302-2838(08)00899-3 PubMedCrossRefGoogle Scholar
  22. 22.
    Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C (2009) Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 115(1):61–67. doi:10.1002/cncr.24009 PubMedCrossRefGoogle Scholar
  23. 23.
    Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R, Rini BI, Bukowski RM (2008) Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 179(1):81–86. doi:S0022-5347(07)02293-8, discussion 86PubMedCrossRefGoogle Scholar
  24. 24.
    Rini BI, Hutson TE, Elson P, Heng DY, Knox JJ, Michaelson D, Choueiri TK, Escudier B (2010) Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma. ASCO GU Cancer Symposium (Meeting article) 145 (abstr 319)Google Scholar
  25. 25.
    Zhou Q, Gustafson D, Nallapareddy S, Diab S, Leong S, Lewis K, Gore L, Messersmith WA, Treston AM, Eckhardt SG, Sidor C, Camidge DR A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. Invest New Drugs. doi:10.1007/s10637-009-9383-9

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Justine Yang Bruce
    • 1
  • Jens Eickhoff
    • 2
  • Roberto Pili
    • 3
  • Theodore Logan
    • 4
  • Michael Carducci
    • 5
  • Jamie Arnott
    • 6
  • Anthony Treston
    • 7
  • George Wilding
    • 8
  • Glenn Liu
    • 9
  1. 1.Section of Hematology/OncologyUniversity of Wisconsin Carbone Cancer Center, Wisconsin Institutes for Medical ResearchMadisonUSA
  2. 2.University of Wisconsin Carbone Cancer CenterMadisonUSA
  3. 3.Roswell Park Cancer InstituteBuffaloUSA
  4. 4.Indiana University Simon Cancer CenterIndianapolisUSA
  5. 5.Sidney Kimmel Comprehensive Cancer CenterBaltimoreUSA
  6. 6.EntreMed, Inc., Research Triangle Park CenterDurhamUSA
  7. 7.EntreMed, Inc.RockvilleUSA
  8. 8.University of Wisconsin Carbone Cancer Center, Wisconsin Institutes for Medical ResearchMadisonUSA
  9. 9.University of Wisconsin Carbone Cancer Center, Wisconsin Institutes for Medical ResearchMadisonUSA

Personalised recommendations